Drug Combination Therapy
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Trial Timeline
Jan 1, 2026 → Dec 31, 2029
NCT ID
NCT07354984About Drug Combination Therapy
Drug Combination Therapy is a phase 2 stage product being developed by Sun Pharmaceutical for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07354984. Target conditions include Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07354984 | Phase 2 | Recruiting |
Competing Products
4 competing products in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MEDI4736 + Tremelimumab + MEDI4736 + Tremelimumab | AstraZeneca | Phase 2 | 35 |
| pepinemab + pembrolizumab | Merck | Phase 1/2 | 32 |
| Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine | Merck | Phase 2 | 42 |
| Nivolumab + Paclitaxel + Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 35 |